FTC Announces Amendments to Hart-Scott-Rodino Rules Regarding Pharmaceutical Patent Licenses

by Holland & Knight LLP
Contact

The Federal Trade Commission (FTC) has announced revisions to the rules under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) that will apply to certain transactions involving the transfer of patent rights in the pharmaceutical and medicine manufacturing industry. The amendments will be effective thirty days after publication in the Federal Register, which should occur soon.

HSR requires parties intending to merge, purchase or sell voting securities, non-corporate interests or assets, or engage in certain other acquisition transactions to provide both the FTC and the Antitrust Division of the Department of Justice (DOJ) with information regarding their operations and the proposed transaction if both the size of transaction and size of person jurisdictional thresholds set forth in the applicable rules are met and no exemption is available. If required, an HSR filing stays the consummation of a covered transaction for the waiting period specified by law based on the law's purpose to allow the FTC and DOJ time to detect and potentially address any perceived anti-competitive effects of a transaction.

Historical HSR Treatment of Licenses

While the term "asset" is not defined in either HSR or its rules, the Premerger Notification Office (PNO) of the FTC has generally interpreted the term in its broadest sense to include all property, both real and personal, tangible and intangible, subject to certain exclusions. In addition, the PNO has stated that the grant of an "exclusive license" to intellectual property where the grantor does not retain any right to use the intellectual property is treated as a transfer of an asset under HSR and is thus a potentially reportable transaction. On the other hand, the PNO has historically stated that the grant of a "non-exclusive license," where the grantor retains the use of the intellectual property and/or the right to grant additional licenses, does not constitute the transfer of an asset under HSR. Thus, the key to determining whether the grant of a license is reportable under HSR has been whether the license is deemed "exclusive" or "non-exclusive" for purposes of HSR — regardless of what the underlying documents may term the license.

Use of Licenses in the Pharmaceutical Industry

With respect to the pharmaceutical industry, the PNO has informally stated in the past that the analysis to determine whether a grant of the exclusive rights to commercially use a patent or part of a patent in the pharmaceutical industry would be deemed an exclusive license was whether the right to "make, use, and sell" the product without restriction was being transferred. In announcing the new rules, however, the FTC asserts that it has become common in recent years for pharmaceutical companies to transfer most but not all of the rights to "make, use, and sell" under an exclusive license. For example, the licensor may retain the right to manufacture under the patent, but only for the licensee. Prior to promulgation of the new rules, the licensor's retention of the right to manufacture would render the license non-exclusive for purposes of HSR and thus the transfer would not be subject to HSR filing requirements. The PNO also cites the increasing frequency of licensors in the pharmaceutical industry retaining the rights to co-develop, co-promote, co-market and co-commercialize the products together with the licensees although the PNO has consistently taken the position that retention by the licensor of co-rights alone does not render a license non-exclusive for purposes of HSR reportability.

New HSR Requirements for Exclusive Licenses of Pharmaceutical Patents

The new rules introduce the concept of an "all commercially significant rights" test to determine whether a license to a pharmaceutical patent is deemed a transfer of the exclusive right to commercially use a patent or a part of a patent and thus an asset transfer reportable under HSR. This test is deemed met if the transfer allows only the recipient of the license to commercially use a pharmaceutical patent, in whole or in part, in a particular "therapeutic area" or specific "indication" within a therapeutic area. A "therapeutic area" for these purposes covers the intended use of the patent, such as for cardiovascular use, and includes all indications. An "indication," on the other hand, focuses on a narrower segment of a therapeutic area, such as Alzheimer's disease within the neurological therapeutic area.

The rules will also now specifically provide that a transfer of assets for purposes of HSR will occur even if the licensor: (1) retains the right to manufacture under a pharmaceutical patent or part of a patent for the licensee, and/or (2) retains co-rights; in each case, such rights will not render the license non-exclusive. On the other hand, exclusive licenses which do not involve the transfer of exclusive rights to use a pharmaceutical patent or part of the patent, such as an exclusive distribution agreement, will not be affected by the new rules.

The PNO states that the new HSR rules regarding treatment of licenses where the licensor retains the right to manufacture exclusively for the licensee is limited to the pharmaceutical industry — not because of the uniqueness of the incentives in the industry, but rather based on the finding that exclusive patent license agreements which transfer all of the rights to commercially use a patent or part of a patent "almost solely occur in the pharmaceutical industry" and that no other industries appear to rely on these types of arrangements. The exclusive license arrangements typically occur where an innovator has discovered and patented a pharmaceutical or biomedical compound but is unable financially to complete the FDA approval process and/or market or promote the product once FDA approval is received. To retain a right to royalties from any future sales of the product, the licensor will enter into an exclusive license agreement with another and usually larger pharmaceutical company rather than a sale of the patent to such a company.

The products of the patents which are the subject of these new rules consist of those whose manufacture and sale would generate revenues in the pharmaceutical and medicine manufacturing industry set forth in the North American Industry Classification System (NAICS) Industry Group 3254. This NAICS group includes medicinal and botanical manufacturing, pharmaceutical preparation manufacturing, in-vitro diagnostic substance manufacturing and biological product manufacturing.

Penalties for Noncompliance

Noncompliance with any requirements under HSR may subject a person, or any officer, director or partner of such person, to civil penalties of up to $16,000 per day for each day of violation. In addition to any monetary penalties, courts may also order compliance with HSR requirements and an extension of the HSR waiting period until substantial compliance has occurred. Courts may also grant certain other equitable relief for any failure by a person to substantially comply with either the HSR premerger notification requirements or with a request by the regulators for additional information once an HSR filing has been made.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Holland & Knight LLP | Attorney Advertising

Written by:

Holland & Knight LLP
Contact
more
less

Holland & Knight LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.